Exelixis Inc. (Nasdaq: EXEL) reported positive results from a Phase 3 study of
cabozantinib to treat patients with metatastic renal cell carcinoma sending the stock price soaring $1.87 to $5.78.
Exelixis reports positive study results
July 20, 2015 at 14:23 PM EDT
